Pushing the boundaries
At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness
ABC PlatformTM
Our biologics-based medicines are built on a proprietary high science Antibody Biopolymer Conjugate or ABC Platform designed to maintain potent and effective drug levels in key ocular tissues for longer than currently available therapies.
Designer Medicines to Solve the Real-World Effectiveness Problem
Antibody biopolymer conjugates are intended to be:
Same Where It Matters
- Clinically proven targets
- Antibody-based biologic
- Intravitreal injection
- Optically clear solution
- No ocular residues
Different Where It Counts
- Designed-in ocular durability
- Fast systemic clearance
- Improved bioavailability
- Improved biocompatibility
- Improved stability
Optimizing size and dose for maximum durability
Size
In general, the larger the size, the longer the molecule will remain in the eye.
Drug per dose
Drug per dose is how many target binding units fit into the injected clinical dose.
Ocular half-life
Ocular half-life is how long the drug lasts in the eye which is a key driver of durability.
CLiP PlatformTM
The power of 500 small molecules in one
Our chemistry-based medicines are built on our proprietary Controlled ‘Living’ Polymerization of phosphorylcholine-containing and drug-containing co-monomers, our CLiP PlatformTM, which is designed to achieve high biocompatibility with high drug loading and sustained release of bioactives for ophthalmology.